KŽKristijonas Žemaitis

Kristijonas Žemaitis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristijonas Žemaitis has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content

    by Mehrnaz Safaee Talkhoncheh, Aurélie Baudet, Fredrik Ek, Agatheeswaran Subramaniam, Yun-Ruei Kao, Natsumi Miharada, Christine Karlsson, Leal Oburoglu, Anna Rydström, Kristijonas Zemaitis, et al.

    Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.


  • Open Access

    The stem cell–supporting small molecule UM171 triggers Cul3-KBTBD4–mediated degradation of ELM2 domain–harboring proteins

    by Kristijonas Žemaitis, Sudip Ghosh, Jenny Hansson, Agatheeswaran Subramaniam


  • Open Access

    RNAi Screen Identifies MTA1 as an Epigenetic Modifier of Differentiation Commitment in Human HSPCs

    by Kristijonas Žemaitis, Agatheeswaran Subramaniam, Roman Galeev, Aurel Prosz, Maria Jassinskaja, Jenny Hansson, Jonas Larsson


  • Genome-wide association study on 13 167 individuals identifies regulators of blood CD34+cell levels

    by Aitzkoa Lopez de Lapuente Portilla, Ludvig Ekdahl, Caterina Cafaro, Zain Ali, Natsumi Miharada, Gudmar Thorleifsson, Kristijonas Žemaitis, Antton Lamarca Arrizabalaga, Malte Thodberg, Maroulio Pertesi, et al.

    Stem cell transplantation is a cornerstone in the treatment of blood malignancies. The most common method to harvest stem cells for transplantation is by leukapheresis, requiring mobilization of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the blood. Identifying the genetic factors that control blood CD34+ cell levels could reveal new drug targets for HSPC mobilization. Here we report the first large-scale, genome-wide association study on blood CD34+ cell levels. Across 13 167 individuals, we identify 9 significant and 2 suggestive associations, accounted for by 8 loci (PPM1H, CXCR4, ENO1-RERE, ITGA9, ARHGAP45, CEBPA, TERT, and MYC). Notably, 4 of the identified associations map to CXCR4, showing that bona fide regulators of blood CD34+ cell levels can be identified through genetic variation. Further, the most significant association maps to PPM1H, encoding a serine/threonine phosphatase never previously implicated in HSPC biology. PPM1H is expressed in HSPCs, and the allele that confers higher blood CD34+ cell levels downregulates PPM1H. Through functional fine-mapping, we find that this downregulation is caused by the variant rs772557-A, which abrogates an MYB transcription factor–binding site in PPM1H intron 1 that is active in specific HSPC subpopulations, including hematopoietic stem cells, and interacts with the promoter by chromatin looping. Furthermore, PPM1H knockdown increases the proportion of CD34+ and CD34+90+ cells in cord blood assays. Our results provide the first large-scale analysis of the genetic architecture of blood CD34+ cell levels and warrant further investigation of PPM1H as a potential inhibition target for stem cell mobilization.


  • Open Access

    Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171

    by Agatheeswaran Subramaniam, Kristijonas Žemaitis, Mehrnaz Safaee Talkhoncheh, David Yudovich, Alexandra Bäckström, Shubhranshu Debnath, Jun Chen, Mayur Vilas Jain, Roman Galeev, Massimiliano Gaetani, et al.

    Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. Here, we report that inhibition of the epigenetic regulator lysine-specific histone demethylase 1A (LSD1) induces a rapid expansion of human cord blood–derived CD34+ cells and promotes in vitro propagation of long-term repopulating HSCs by preventing differentiation. The phenotype and molecular characteristics of cells treated with LSD1 inhibitors were highly similar to cells treated with UM171, an agent promoting expansion of HSCs through undefined mechanisms and currently being tested in clinical trials. Strikingly, we found that LSD1, as well as other members of the LSD1-containing chromatin remodeling complex CoREST, is rapidly polyubiquitinated and degraded upon UM171 treatment. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 depletion of the CoREST core member, RCOR1, resulted in expansion of CD34+ cells similar to LSD1 inhibition and UM171. Taken together, LSD1 and CoREST restrict HSC expansion and are principal targets of UM171, forming a mechanistic basis for the HSC-promoting activity of UM171.


  • Open Access

    Efficient and nontoxic biomolecule delivery to primary human hematopoietic stem cells using nanostraws

    by Ludwig Schmiderer, Agatheeswaran Subramaniam, Kristijonas Žemaitis, Alexandra Bäckström, David Yudovich, Svetlana Soboleva, Roman Galeev, Christelle N. Prinz, Jonas Larsson, Martin Hjort

    Significance: Primary stem cells are difficult to transfect, and their viability and function are impaired by traditional transfection methods. We show that nanostraws can be used to deliver RNA to primary human hematopoietic stem cells without any detectable negative effects. Nanostraw-treated cells show no alterations in gene expression and fully retain their proliferative capacity and their potential to regenerate blood cells of different lineages in vivo. This nonperturbative transfection method can benefit functional studies and clinical applications where minimal impact on stem cell function and viability is required.